Amgen pricing benchmark five-part offering of senior notes Monday

By Aleesia Forni

Virginia Beach, May 19 - Amgen Inc. is in Monday's market with a benchmark offering of senior notes in five tranches, according to a market source and a 424B3 filed with the Securities and Exchange Commission.

The sale will include fixed- and floating-rate tranches of notes due 2017 and 2019, along with a tranche of fixed-rate notes due 2024.

Morgan Stanley & Co. LLC is the global coordinator for all five tranches of notes.

Barclays and Goldman Sachs & Co. are the joint bookrunners for the three- and 10-year tranches, while Citigroup Global Markets Inc. and J.P. Morgan Securities LLC are the bookrunners for the notes due 2019.

Proceeds will be used to either repurchase all of subsidiary ATL Holdings Ltd.'s class A preferred shares or to repay the company's term loan credit agreement. Remaining proceeds will be used to repay debt and for general corporate purposes.

The manufacturer and marketer of human therapeutics based upon advances in cellular and molecular biology is based in Thousand Oaks, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.